Intraoperative intravitreal triamcinolone acetonide injectio
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Researchers aimed to evaluate the efficacy and safety of phacoemulsification with intravitreal 3mg triamcinolone acetonide injection in preventing postoperative inflammation and complications in patients with non-infectious anterior uveitis and panuveitis complicated cataract.

In this retrospective cohort study, 140 uveitic cataract patients who received phacoemulsification and intraocular lens implantation were reviewed. The IVTA group received intravitreal injection of 3mg triamcinolone acetonide (TA) at the end of surgery, and the control group (51 eyes of 41 patients) without injection matched by propensity score matching were enrolled.

Outcome measures were best corrected visual acuity (BCVA), anterior chamber inflammation, intraocular pressure, corneal endothelial cell density, central macular thickness and complications within 3 months follow-up.

Results:
--The degree of postoperative anterior chamber inflammation in the IVTA group was lighter than that in the control group.

--The postoperative logMAR BCVA of anterior uveitis was better and improved more quickly in the IVTA group.

--Postoperative time of using corticosteroids was shorter in the IVTA group as compared to the control group.

--The central macular thickness at postoperative month 1 was statistically significantly lower in the IVTA group. There were no statistically significant differences between the two groups in postoperative corneal endothelial cell density and intraocular pressure.

--2 of 51 eyes in the IVTA group and 8 of 51 eyes in the control group had recurrence of uveitis; 6 of 45 eyes in the control group developed cystoid macular edema but none in the IVTA group; 11 of 51 eyes in the IVTA group and 22 of 51 eyes in the control group developed posterior synechiae postoperatively.

In conclusion, intraoperative intra-vitreous 3 mg TA injection is an effective and safe supplementary therapy designed to avoid post-operative inflammation and to promote early recovery in post-operative uveitis patients or cataract complex panuveitis.

Source: https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-021-02017-y
Like
Comment
Share